M3, Inc. (MTHRY) Stock Price & Analysis
M3, Inc. (MTHRY) — price $5.50 (-0.36%), as of the Oct 2, 2026 trading session; market cap $7.34B.
Educational signal · not a buy or sell recommendation · How to read this
M3, Inc. · MTHRY · Healthcare · Medical - Healthcare Information Services
M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians…
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.50 | |
| Change on the day | -0.36% | |
| 52-week range | $3.97 – $8.85 | |
| Market capitalisation | $7.34B | |
| Price / earnings (trailing) | 25.72 | |
| Shares traded on the day | 3.7K | |
| Beta (volatility vs the S&P 500) | 0.48 | |
| Dividends per share (last 12 months) | $0.04 | |
| Dividend yield (last 12 months) | 0.74% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for M3 (MTHRY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the MTHRY film — every key number, told as a short cinematic story
~2 min · open the film
What is M3 (MTHRY), and what does it report?
Short answer · as of
M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians… Healthcare / Medical Healthcare Information Services Headquarters: Akasaka Intercity, Tokyo, TY, 107-0052, JP. It employs 17,010 people and is led by Itaru Tanimura. In Q1 FY2027 it reported revenue of $578M and net income of $58M. The market values it at $7.34B.
What do the latest results show for M3 (MTHRY)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $578M.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $554.30M Apr 30, 2026
- Latest report · revenue estimate
- $565.36M Apr 30, 2026
- Latest report · revenue vs estimate
- Below estimate Apr 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Apr 30, 2026 | $554.30M | $565.36M | $0.0354 | Not available |
| Feb 9, 2026 | $607.46M | $609.56M | $0.0908 | Not available |
| Oct 28, 2025 | $574.25M | $559.83M | $0.0544 | Not available |
| Jul 28, 2025 | $595.24M | $570.08M | $0.0004 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $578M | $58M | $0.04 (diluted) |
| Q4 FY2026 | $561M | $48M | $0.04 (diluted) |
| Q3 FY2026 | $603M | $122M | $0.09 (diluted) |
| Q2 FY2026 | $545M | $70M | $0.05 (diluted) |
What are the financial strengths and risks for M3 (MTHRY)?
Short answer
The distress and quality screens read Altman Z 5.67 · Piotroski F 5. Trailing ratios: ROE 11.5% · ROA 7.3% · current ratio 2.84 · earnings yield 3.9%.
What should you watch next at M3 (MTHRY)?
Research dated 2026-09-13.
Investors monitoring the stock should track whether actual revenue can close the gap with analyst projections, as recent periods have shown actual results trailing consensus estimates.
Another key observation point is the progression of the international segment, particularly the European and American practitioner networks. Continued scaling in those overseas portals is required to validate the strategy of replicating its domestic pharmaceutical marketing success in foreign regulatory environments.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is M3 scored?
Research dated 2026-09-13.
Unlike conventional digital advertising networks that monetize broad consumer traffic, this platform generates value exclusively through a highly restricted audience of medical practitioners.
When compared to traditional contract research organizations or healthcare staffing firms, this business derives its advantage from a captive user base, allowing it to source clinical trial participants and job candidates directly from its own portals. This integrated approach reduces acquisition costs significantly compared to standalone medical recruiters.
| Company | Price | Market value | Score |
|---|---|---|---|
| $58.79 Oct 2, 2026 | $12.0B | — Model unavailable | |
| $0.64 Oct 2, 2026 | $10.2B | — Model unavailable | |
| $1.46 Oct 2, 2026 | $8.46B | — Model unavailable | |
| $45.55 Oct 2, 2026 | $9.61B | — Model unavailable | |
| $11.13 Oct 2, 2026 | $7.57B | — Model unavailable | |
| $90.04 Oct 2, 2026 | $7.53B | — 5-pillar · not comparable | |
| $97.67 Oct 2, 2026 | $7.56B | — 5-pillar · not comparable | |
| $27.93 Oct 2, 2026 | $5.22B | — 5-pillar · not comparable | |
| $60.25 Oct 2, 2026 | $11.8B | — 5-pillar · not comparable | |
| $93.50 Oct 2, 2026 | $11.9B | — 5-pillar · not comparable | |
| $49.32 Oct 2, 2026 | $4.25B | — 5-pillar · not comparable | |
| $76.63 Oct 2, 2026 | $13.4B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
Common Questions About MTHRY (Healthcare)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is MTHRY a good stock to buy?
Stock Expert AI does not rate MTHRY buy, sell or hold. M3, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MTHRY stock price today?
The last price recorded on this page for M3, Inc. (MTHRY) is $5.50, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for MTHRY?
Evaluate MTHRY on fundamentals, analyst consensus, and risk factors. P/E: 25.72x. Not financial advice.
How frequently does MTHRY data refresh on this page?
MTHRY's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MTHRY's recent stock price performance?
(MTHRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive global network of healthcare professionals on its digital platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MTHRY overvalued or undervalued right now?
(MTHRY) trades at 25.72x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MTHRY before investing?
Before investing in M3, Inc. (MTHRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MTHRY to a portfolio?
Key strength of M3, Inc. (MTHRY): Extensive global network of healthcare professionals on its digital platforms. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (34 figures)
The 34 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 27 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $5.50 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T14:54:30.785Z. | |
px.change | Change on the day | -0.36% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $7.34B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T14:54:29.187Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians… | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.02 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 25.72 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.7K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.48 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Healthcare Information Services | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Akasaka Intercity, Tokyo, TY, 107-0052, JP | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 17,010 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Itaru Tanimura | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q1 FY2027 | $578M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2027 | $58M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-04-30.revenue_actual | Revenue · reported — report date 2026-04-30 | $554.30M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_estimated | Revenue · estimate — report date 2026-04-30 | $565.36M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_actual | EPS · reported — report date 2026-04-30 | $0.0354 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.revenue_actual | Revenue · reported — report date 2026-02-09 | $607.46M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.revenue_estimated | Revenue · estimate — report date 2026-02-09 | $609.56M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.eps_actual | EPS · reported — report date 2026-02-09 | $0.0908 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_actual | Revenue · reported — report date 2025-10-28 | $574.25M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_estimated | Revenue · estimate — report date 2025-10-28 | $559.83M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $0.0544 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-28.revenue_actual | Revenue · reported — report date 2025-07-28 | $595.24M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-28.revenue_estimated | Revenue · estimate — report date 2025-07-28 | $570.08M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-28.eps_actual | EPS · reported — report date 2025-07-28 | $0.0004 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $3.97 – $8.85 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 5.67 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 11.5% · ROA 7.3% · current ratio 2.84 · earnings yield 3.9% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.04 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.74% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-04-30.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($554.30M) with the recorded estimate ($565.36M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-04-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-04-30.revenue_actual,earn.history.depth.2026-04-30.revenue_estimated,earn.history.depth.2026-04-30.revenue_actual.comparison,earn.history.depth.2026-04-30.eps_actual,earn.history.depth.2026-02-09.revenue_actual,earn.history.depth.2026-02-09.revenue_estimated,earn.history.depth.2026-02-09.eps_actual,earn.history.depth.2025-10-28.revenue_actual,earn.history.depth.2025-10-28.revenue_estimated,earn.history.depth.2025-10-28.eps_actual,earn.history.depth.2025-07-28.revenue_actual,earn.history.depth.2025-07-28.revenue_estimated,earn.history.depth.2025-07-28.eps_actual.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-04-30 | FMP | Financial Modeling Prep (FMP) earnings |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Business description | M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians and other healthcare professionals. The company organizes its operations across five distinct reporting divisions: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several key digital platforms. Its flagship, m3.com, serves as an exclusive online portal providing vital information to healthcare practitioners. Through MR-kun, member doctors gain continuous and independent access to information within the m3.com ecosystem. QOL-kun offers members non-medical lifestyle support, while AskDoctors enables the general public to pose health and illness questions, which are then addressed by registered physicians. Internationally, M3 operates MDLinx for medical professionals in the United States and Doctorsnetuk, a platform that provides development services for pharmaceutical companies and hosts drug information databases for France, Germany, and Spain. Additionally, m3com CAREER facilitates career support services for medical and pharmaceutical professionals. Beyond these platforms, M3 engages in a wide array of activities, including the sales and marketing of pharmaceutical products and medical devices. The company is also involved in developing, selling, and supporting electronic medical record systems and medical equipment for healthcare facilities, conducting professional surveys for medical practitioners, and offering online sales and marketing assistance to pharmaceutical firms. Furthermore, M3 provides management support and consulting services to medical institutions, operates home-visit nursing services, supplies human resources solutions for the healthcare sector, and manages clinical research facilities. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Trailing twelve-month ratio set | Quick ratio: 2.84; Current ratio: 2.84; Debt to equity: 0.09; Net margin: 13%; Gross margin: 49.5%; Operating margin: 19.2%; Return on assets: 7.3%; Return on equity: 11.5% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Healthcare Information Services | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.